4 March 2022 - PHARMAC has heard from our expert advisors and clinicians treating people with COVID-19 that we need to make further changes to the temporary access criteria for remdesivir.

“This week we have heard that to better target treatment to people who are most at risk, we need to further refine the access criteria. Our expert advisors and clinicians were concerned that the access criteria were too wide in the current context, and it would be used by those not at most risk."

Read PHARMAC press release